A consensus statement on clinical trials of bypassing agent prophylaxis in inhibitor patients.
(2011) In Haemophilia 17. p.516-521- Abstract
- Summary. The haemophilia literature increasingly contains reports describing the use of bypassing agent prophylaxis (BAP) in patients with severe haemophilia A and inhibitors. However, it is difficult to interpret and compare the results and draw conclusions about treatment efficacy because of small patient numbers and a lack of standardization among BAP studies. This article presents consensus recommendations for standardizing future BAP clinical trials developed by an international panel of haemophilia opinion leaders.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1884425
- author
- Teitel, J ; Berntorp, Erik LU ; Dolan, G ; Fischer, K ; Gringeri, A ; Kessler, C ; Lambert, T ; Leissinger, C ; Nemes, L and Shima, M
- organization
- publishing date
- 2011
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Haemophilia
- volume
- 17
- pages
- 516 - 521
- publisher
- Wiley-Blackwell
- external identifiers
-
- wos:000289894200020
- pmid:21371181
- scopus:79955154649
- pmid:21371181
- ISSN
- 1351-8216
- DOI
- 10.1111/j.1365-2516.2010.02440.x
- language
- English
- LU publication?
- yes
- id
- 46151289-04c0-47cf-93ea-670d6af687a5 (old id 1884425)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/21371181?dopt=Abstract
- date added to LUP
- 2016-04-04 07:07:19
- date last changed
- 2022-04-06 11:28:00
@article{46151289-04c0-47cf-93ea-670d6af687a5, abstract = {{Summary. The haemophilia literature increasingly contains reports describing the use of bypassing agent prophylaxis (BAP) in patients with severe haemophilia A and inhibitors. However, it is difficult to interpret and compare the results and draw conclusions about treatment efficacy because of small patient numbers and a lack of standardization among BAP studies. This article presents consensus recommendations for standardizing future BAP clinical trials developed by an international panel of haemophilia opinion leaders.}}, author = {{Teitel, J and Berntorp, Erik and Dolan, G and Fischer, K and Gringeri, A and Kessler, C and Lambert, T and Leissinger, C and Nemes, L and Shima, M}}, issn = {{1351-8216}}, language = {{eng}}, pages = {{516--521}}, publisher = {{Wiley-Blackwell}}, series = {{Haemophilia}}, title = {{A consensus statement on clinical trials of bypassing agent prophylaxis in inhibitor patients.}}, url = {{http://dx.doi.org/10.1111/j.1365-2516.2010.02440.x}}, doi = {{10.1111/j.1365-2516.2010.02440.x}}, volume = {{17}}, year = {{2011}}, }